Suppr超能文献

2009 年至 2018 年在瑞士巴塞尔大学医院接受双瓣手术的患者的结局。

Outcome of patients with double valve surgery between 2009 and 2018 at University Hospital Basel, Switzerland.

机构信息

Department of Cardiac Surgery, University Hospital Basel, University Hospital Basel, 4031, Basel, Switzerland.

University of Basel, 4051, Basel, Switzerland.

出版信息

J Cardiothorac Surg. 2022 Jun 13;17(1):152. doi: 10.1186/s13019-022-01904-9.

Abstract

BACKGROUND

In isolated mitral valve regurgitation general consensus on surgery is to favor repair over replacement excluding rheumatic etiology or endocarditis. If concomitant aortic valve replacement is performed however, clinical evidence is more ambiguous and no explicit guidelines exist on the choice of mitral valve treatment. Both, double valve replacement (DVR) and aortic valve replacement in combination with concomitant mitral valve repair (AVR + MVP) have been proven to be feasible procedures. In our single-center, retrospective, observational cohort study, we compared the outcome of these two surgical techniques focusing on mortality and morbidity.

METHODS

89 patients underwent DVR (n = 41) or AVR + MVP (n = 48) in our institution between 2009 and 2018. Follow-up data was collected using electronic patient records, by contacting treating physicians and by telephone interviews. We used the Kaplan-Meier method to analyze mortality during follow-up and Cox regression to investigate potential predictors of mortality.

RESULTS

During a median follow-up duration of 4.5 [IQR 2.9 to 6.1] years, there was no significant difference in mortality between both cohorts. Thirty days mortality was 6.3% in the DVR and 7% in the AVR + MVP cohort. Overall mortality amounted to 17% for DVR and 23% for AVR + MVP. DVR was the preferred procedure for valve disease of rheumatic etiology and for endocarditis, while in degenerative valves AVR + MVP was predominant. More biological valves were used in the AVR + MVP cohort (p < 0.001) and more mechanical valves were implanted in the DVR cohort. The rate of rehospitalization, deterioration of left ventricular ejection fraction and postoperative complications were equally distributed among the two cohorts.

CONCLUSION

Our data analysis showed that both DVR and AVR + MVP are safe and feasible options for double valve surgery. Based on our findings we could not prove superiority of one surgical technique over the other. Choosing the appropriate procedure for the patient should be influenced by valve etiology, patients' comorbidities and the surgeons' experience.

TRIAL REGISTRATION

This was a retrospectively registered trial, registered on April 1st 2018, ClinicalTrials.gov Identifier: NCT03667274.

摘要

背景

在孤立性二尖瓣反流中,普遍共识是优先选择修复而非置换,除非病因是风湿性或心内膜炎。然而,如果同时进行主动脉瓣置换,临床证据则更为模糊,对于二尖瓣处理方式的选择也没有明确的指南。双瓣置换(DVR)和主动脉瓣置换联合同期二尖瓣修复(AVR+MVP)均已被证明是可行的手术。在我们的单中心回顾性观察队列研究中,我们比较了这两种手术技术的结果,重点关注死亡率和发病率。

方法

2009 年至 2018 年期间,我们机构有 89 例患者接受了 DVR(n=41)或 AVR+MVP(n=48)手术。使用电子病历、联系主治医生和电话访谈收集随访数据。我们使用 Kaplan-Meier 法分析随访期间的死亡率,并使用 Cox 回归分析死亡率的潜在预测因素。

结果

在中位随访 4.5[IQR 2.9 至 6.1]年期间,两组之间的死亡率无显著差异。DVR 组的 30 天死亡率为 6.3%,AVR+MVP 组为 7%。DVR 的总死亡率为 17%,AVR+MVP 为 23%。DVR 是风湿性病因和心内膜炎的首选手术方式,而在退行性瓣膜病变中,AVR+MVP 则更为常见。AVR+MVP 组更多使用生物瓣膜(p<0.001),DVR 组更多使用机械瓣膜。两组的再住院率、左心室射血分数恶化率和术后并发症发生率相当。

结论

我们的数据分析表明,DVR 和 AVR+MVP 都是双瓣手术的安全可行选择。根据我们的发现,我们无法证明一种手术技术优于另一种。为患者选择合适的手术方式应考虑瓣膜病因、患者合并症和外科医生的经验。

试验注册

这是一项回顾性注册试验,于 2018 年 4 月 1 日在 ClinicalTrials.gov 注册,注册号:NCT03667274。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12bd/9190140/48a7b675f143/13019_2022_1904_Fig2_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验